OUD & MAR: Caring for Our Communities

Similar documents
Opioid Use Disorder and Medication Assisted Recovery: Caring For Our Communities

OUD & MAR: Caring for Our Communities Maine Independent Clinical Information Service 2018 Opioid Educational Outreach Module.

TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS

Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations

Opioid Use Disorders &Medication Treatment

8/16/2018. California s MAT Expansion Hub and Spoke System: Provider and Consumer Perspectives. Agenda. No Wrong Door

MORPHINE MILLIGRAM EQUIVALENTS (MMEs) Elisabeth Fowlie Mock, MD, MPH, FAAFP Maine Quality Counts Caring For ME Webinar 11/8/2016

NORTHWEST AIDS EDUCATION AND TRAINING CENTER. Opioid Use Disorders. Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014

Changing Course: statewide efforts to combat the opioid epidemic in California

Addressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention

Opiate Use Disorder and Opiate Overdose

An Alternative Payment Model Concept for Office-based Treatment of Opioid Use Disorder

CDC Guideline for Prescribing Opioids for Chronic Pain. Centers for Disease Control and Prevention National Center for Injury Prevention and Control

Medication Assisted Treatment

Buprenorphine and MAT 101

Massachusetts Responds to the Opioid Epidemic Using Data To Inform Policy and Programs. Monica Bharel, MD MPH Commissioner of Public Health

Opioid Review and MAT Clinic CDC Guidelines

Methadone and Naltrexone ER

It s Not Just One More Thing! Overcoming Obstacles for Buprenorphine Treatment by Residents, Faculty and Programs

MICIS 2017 REPORT January 1 - December 31, 2017

Medication-Assisted Treatment. What Is It and Why Do We Use It?

Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings

Mobilizing a Response to the Opioid Epidemic: County Snapshots. Kelly Pfeifer, MD May 10, 2018

MAT in the Corrections Setting

What would it take to get to zero overdose deaths in California? Kelly Pfeifer, MD May 5, 2017

Opioid Use in Youth. Amy Yule M.D. March 2,

New Guidelines for Opioid Prescribing

CDC Guideline for Prescribing Opioids for Chronic Pain

4/19/2018. Opioid Use Disorder in Pregnancy OBJECTIVES ANTENATAL TESTING

QUARTERLY PROVIDER MEETING MARCH 9, 2017 SUZANNE BORYS, ED.D.

Opioid Use Issues: All the Players

Treatment Alternatives for Substance Use Disorders

The Role of Primary Care Teams and the Medical Neighborhood in Addressing the Opioid Crisis in Maine. March 10, 2016

Linking Opioid Treatment in Primary Care. Roxanne Lewin M.D.

NEW APPROACHES TO DISSEMINATING TREATMENT:

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center

OPIOID SAFE- PRESCRIBING TRAINING IMMERSION (OSTI)

Buprenorphine Prescribing as a Patient- Centered Medical Home Enhancement

Patient and Family Agreement on Opioids

Providing Medication Assisted Treatment for Opioid Use Disorder in Family Medicine Clinics in Vermont

NALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018

Working with People Who Use Drugs in HIV Care Settings. August 29, 2017 Workshop C 2:00 3:30 p.m.

Building capacity for a CHC response to Ontario's Opioid Crisis

What Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016

Closing the Loop in Treating Opioid Addiction:

Medication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc.

DHCS Tribal MAT Project

An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT

Hospitals Role in Addressing the Opioid Crisis

Understanding and Combating the Heroin Epidemic

State Opioid Response (SOR) Grant

Opioid Prescribing Improvement Program

What is the strategy?

New Guidelines for Prescribing Opioids for Chronic Pain

Understanding Medication in Addiction Treatment for Drug Court Participants

Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse. Jill M Williams, MD

Note: The trainings below represent a foundational list, and may be adapted based on audience and need.

Medications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC

Opioid Use Disorder Treatment Initiation in Diverse Settings

Health Systems and Addiction: Provider Issues

Agenda. 1 Opioid Addiction in the United States. Evidence-based treatments for OUD. OUD Treatment: Best Practices. 4 Groups: Our Model

Can 12 Step and Medications for Substance Use Disorders Co-Exist?

The Social Worker s Role in Medication Assisted Treatment

Responding to the Opioid Epidemic

Opioid Use Disorder Treatment: Buprenorphine Treatment Basics

Mission: The Oregon Coalition for Responsible Use of Meds (OrCRM) is a Statewide Coalition launched to prevent overdose, misuse and abuse of

Clinical Guidelines for the Pharmacologic Treatment of Opioid Use Disorder

Aetna s Initiative on the Opioid Epidemic

STARTING SUBOXONE IN PRIMARY CARE

OPIOIDS IN AMERICA. A complex crisis. A comprehensive response.

Management of Opioid Use Disorder in Primary Care

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine

California Hub and Spoke System Evaluation

Rule Governing the Prescribing of Opioids for Pain

Opioids 101. Washington Prevention Summit. Alison Newman, MPH November 6, 2018

Buprenorphine 2.0: I have my waiver, now what? Dr. Ritu Bhatnagar, M.D., M.P.H. Dr. John Ewing, M.D., FASAM. Disclosures

Identification and Treatment of Opioid Use Disorders in Primary Care Settings

Jerry Cochran, MSW, PhD University of Utah School of Medicine Department of Internal Medicine Department of Psychiatry

It Takes A Village to Curb the Prescription Opioid Epidemic: Supply healthcare providers with resources to improve patient safety

Community Engagement to Address the Opioid Crisis. Laura Palombi, PharmD, MPH, MAT, AE-C

Methadone and Naltrexone ER

Child Welfare and MOMS: Building Partnerships to Improve Care

Vermont Hub and Spoke Model Treatment Need Questionnaire

Wasted AN INTRODUCTION TO SUBSTANCE ABUSE

9/17/2018 MISSION IMPOSSIBLE: IF YOU CHOOSE TO ACCEPT MISSION JOIN JUSTICE LEAGUE I M POSSIBLE HEPBURN

2/21/2018. What are Opioids?

Helping Recovery Residences Adapt

Disclosures. Objectives 2/5/2018. Women and opioid use disorder: Optimizing care during pregnancy and beyond

Policy and Political Dynamics of the Opioid Addiction Crisis in the United States

Management Options for Opioid Dependence:

The Importance of Psychological Treatment and Behavioral Support

NURSING FOLLOW-UP: BUPRENORPHINE/NALOXONE BUPRENORPHINE/NALOXONE CLINIC VISITS

Caring for ME Lunch & Learn Webinar

Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates

SC MAT ACCESS. Medication Assisted Treatment Academic Community Capacity Expansion for Sustainable Success Kathleen Brady, MD, PhD, VPR, MUSC

Note: The trainings below represent a foundational list, and may be adapted based on audience and need.

Trends and Challenges: The Kentucky Opioid Crisis. Jason Smith, MD PhD University of Louisville

Opioid Withdrawal, Opioid Substitution Treatment, and HIV Infection

FIGHTING THE OPIOID EPIDEMIC- ONE PRACTICE CAN MAKE A DIFFERENCE IN YOUR COMMUNITY.

The Opiate Crisis 4/6/18. April 9, Words are important. If you want to care for something, you call it a flower.

Transcription:

OUD & MAR: Caring for Our Communities

Speaker: Elisabeth Fowlie Mock, MD, MPH

Video Resources Diversion Alert/recoveryinme video https://www.youtube.com/watch?v=q1lsmwwwm40 CDC Videos RX Awareness Campaign Trailer (1:53) & Brenda s Rx Awareness Story (0:30) How can I be addicted to these? I get them from my doctor. It kills your soul and makes you feel worthless. https://www.cdc.gov/rxawareness/resources/video.html Leighton MAT trailer https://www.youtube.com/watch?v=wjtyp_pmuqi

Disclosures MICIS does not accept any money from pharmaceutical companies This presentation includes off label use of medications

Objectives At the conclusion of the MICIS learning session, the learner will have the ability to: 1. Appropriately recognize, diagnose and language opioid use disorder (OUD) 2. Compare pharmacologic treatments used in Medication Assisted Recovery (MAR) 3. Develop a strategy for treating acute pain for patients with OUD 4. Constantly consider harm reduction

Materials May Include un-ad one page handout for each topic How to Use Naloxone (pt brochure) ME Law slides/chapter 21 rules DHHS prescription guide National/state numbers Evidence & Resource document at MICISMAINE.org

Opioid Use Disorder is a Chronic Disease typically, a chronic, relapsing, yet treatable illness; associated with significantly increased rates of morbidity and mortality (Strain, 2018)

U.S. life expectancy declined for 2 years in a row (2014-2016), largely because of unintentional injuries (includes unintentional OD). (NCHS Data Brief No. 293, 2016)

10

Maine Overdose Deaths

Challenge Question Name the four counties in Maine that had OD deaths higher than proportion to population size (from Attorney General OD report, 2017 statistics)

2017 Overdose Deaths by County <10 Deaths higher than proportion to population size 2017 Drug Deaths Report ME Attny Genl s Office <10 18 <10 47 <10 11 65 <10 13 Deaths proportional to population size 109 25 <10 Slide courtesy of Lisa Letourneau/ME Quality Counts 82 13

Opioid-related ED Visits July 2016 Sept 2017 Increase of 34% in Maine Massachusetts, New Hampshire, Rhode Island had nonsignificant decreases (<10%) Maine noted to be one of 16 states with high prevalence of overdose mortality (Vivolo-Kantor, 2018)

There are several studies that demonstrate the negative impact of using demeaning, pejorative, or stigmatizing language such language doesn t just hurt feelings the research shows that when such language is used people are less likely to get the medical care they so desperately need. - Omar Manejwala, MD, Addiction Specialist

OUD/MAR Myths Exercise

We Need to Be Prepared to Recognize and Treat OUD

Review/fill-in the diagnostic criteria for OUD Two Larger Desire Time Craving Failure Despite Given up Hazardous Caused

Recovery a process of change improving health and wellness living a self-directed life striving to reach full potential no one size fits all approach (SAMSHA, 2012)

10 Guiding Principles of Recovery (SAMSHA, 2012)

Four Dimensions that Support a Life in Recovery Health Home Purpose Community (SAMSHA website)

MAR: Effective, Cost-effective, Medications: and Cost-beneficial reduce illicit opioid use retain people in treatment reduce risk of opioid overdose death better than treatment with placebo or no medication

Who Can Prescribe? Buprenorphine, Methadone, Emergency methadone or buprenorphine (72h), Naltrexone

Newer Buprenorphine Formulations subdermal implant (6 months) injection (monthly)

Naltrexone Initiation of naltrexone must be preceded by withdrawal from opioids (preferably medically supervised); oral naltrexone has higher dropout rates than injectable.

Recovery Occurs via Many Pathways one year recovery rates: 50% with medication-assistance, 10% without medication (multiple sources cited in references)

Which Patients Are Best Suited for tx in Primary Care Settings?

Hub & Spokes Collaborate Hubs Spokes Patients Information High intensity MAT Methadone, buprenorphine, naltrexone Regional locations All staff specialize in addictions treatment Consultation Training Maintenance MAT Buprenorphine, naltrexone Community locations Lead provider + nurse and LADC/MA counselor

National Buprenorphine Data 2% of all prescribers have an x-waiver ~50% of those ever prescribe ~50% of those prescribe 1-4 patients (SAMSHA)

Maine Buprenorphine Prescribers PAs (30 limit*) Docs (275 limit) NPs (30 limit*) Docs (100 limit) Docs (30 limit) *all NP/PA are in first year of license with 30 pt limit Data: SAMSHA, January 2018, Abstracted by Lisa Letourneau, MD, MPH

How long to treat? Indefinite. Some patients: may slowly taper and wean after 1-2 years of stability remain on low dose therapy long-term may go on and off treatment

Acute Pain in Patients with OUD

Bias may be a Barrier Emergency physicians at Hopkins had lower regard for pts with SUDs than other medical conditions with behavioral components. 54 % at least somewhat agree that they prefer not to work pts with SUD who have pain (Mendiola, 2018)

Baseline opioid maintenance therapies are not adequate for pain control in patients with acute, moderate to severe injuries and surgeries beyond minor procedures.

In Patients on Methadone and Buprenorphine: verify the dose maximize nonopioid pain treatments (pharmacologic and nonpharmacologic) consider increasing or splitting dose add higher dose short-acting opioids for 3-5d

Actively using heroin/other opioid: try to get a history of dose maximize non-opioid modalities consider tramadol always try to use oral medications in preference over IV consider increased doses post-operatively avoid take-home prescriptions in most cases

In Patients on Naltrexone: try to delay elective interventions maximize nonopioid pain treatments (pharmacologic and nonpharmacologic) if emergency may need higher than usual doses of opioids to overcome high risk of respiratory depression

Contact recovery medication prescriber proactively or as soon as possible in unscheduled/emergent situations to discuss acute pain needs, taper schedule, and who will handle prescribing

Hardwire Harm Reduction Strategies in All Medical Practices

SAVE LIVES FIRST Harm Reduction

Social Determinants of Health Contribute to the Opioid Epidemic Homeless persons were 9x more likely to die from OD than persons stably housed. A housing first approach to recovery increases likelihood of success. (Baggett, 2013)

Social Determinants of Health Contribute to the Opioid Epidemic Persons who are released from incarceration are at a 12x risk of overdose. Most jails/prisons do not provide MAR.

Harm Reduction Prescribe opioids using conservative management strategies Limit supplies to 3-5 days for acute pain Avoid co-prescribing with BZDP Exhaust nonopioid and nonpharmacologic treatment strategies (for acute or chronic) Document informed consent

Consider Naloxone Prescriptions for: all patients on chronic opioids, especially at doses over 50 MME any patient co-prescribed benzodiazepines/sedatives or actively using alcohol friends or family members who might witness overdose patients with OUD being released from incarceration or treatment programs patients with history of overdose patients with underlying respiratory disease, especially sleep apnea all patients in MAR

In Summary...

The words you use to describe OUD and an individual with OUD are powerful. Recovery is possible and more likely when using medications combined with counselling OUD medications reduce illicit opioid use, reduce overdose deaths, decrease crime and retain people in treatment/counselling Treat acute pain with multiple modalities for all patients, including those in recovery Recommend naloxone prescriptions for all patients in recovery

MICISTravels on facebook references: MICISMaine.org

The words you use to describe OUD and an individual with OUD are powerful. Providers should adopt terminology that will not reinforce prejudice, negative attitudes, or discrimination. - Omar Manejwala, MD, Addiction Specialist

Counselors help clients by addressing the challenges & consequences of OUD

Maine Overdose Deaths 450 400 350 300 250 200 150 100 50 0 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Total Deaths Pharmaceutical Opioid Deaths Illicit Opioid Deaths

Words are important. If you want to care for something, you call it a flower ; if you want to kill something, you call it a weed. - Don Coyhis, Native American Recovery coach

Use of marijuana, stimulants, or other addictive drugs should not be a reason to suspend OUD tx. However, evidence demonstrates pts actively using substances during OUD tx have a poorer prognosis. The use of EtOH, bzdp and other sedative hypnotics may be a reason to suspend agonist tx safety concerns related to respiratory depression. (ASAM Guideline, 2015)